This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

UCB And IBM Collaborate To Personalize Care For Epilepsy Patients

Stocks in this article: IBM

"Technologies, like analytics and cognitive computing applied to big data, are revolutionizing the way we deliver and receive care," said Robert Merkel, Global Healthcare and Life Sciences Industry Leader, IBM Global Business Services. "IBM is dedicating innovation and expertise to help UCB prove the predictive value of this technology that would arm physicians with information that will help them identify the best possible treatment options and improve quality of care for patients suffering from epilepsy."

As part of its open innovation model, UCB may look to collaborate with additional leaders in the epilepsy and healthcare technology communities to develop and broaden the reach of this project and improve long-term patient outcomes.

Phil Gattone, M.Ed., CEO of the Epilepsy Foundation and participant in the project's advisory board said, "The Epilepsy Foundation is very excited about the potential of this innovative approach for more personalized treatment management of epilepsy patients. Individuals fighting epilepsy and their care providers deserve the most current information to help them make informed decisions about their care in a timeframe that matters. This collaboration could benefit patients, their families and the healthcare system in a unique way."

For further information UCB

France Nivelle, Global Communications, UCBT +32.2.559.9178, france.nivelle@ucb.com  

Laurent Schots, Media Relations, UCBT +32.2.559.9264, laurent.schots@ucb.com  

For further information IBM

Holli Haswell, IBM External Relations T +1.720.396.5485, hhaswell@us.ibm.com

Notes to the editor

About UCB UCB, Brussels, Belgium ( www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9,000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

About UCB Research Collaborations UCB has adopted an open innovation model in which internal and external experts collaborate to address unmet needs for people living with severe diseases of the immune system and the central nervous system. As part of its commitment to raising the standard of care for patients, UCB is building these long-term collaborations and super networks with leading researchers and institutions to use cutting-edge scientific research and technology to deliver unique patient solutions.

About IBM To learn more about IBM's Big Data and Analytics services, please visit: http://www-935.ibm.com/services/us/gbs/business-analytics/ Follow us on Twitter @IBMHealthcare or www.twitter.com/ibmhealthcare  Join in the discussion on the Smarter Healthcare LinkedIn Group  Watch our videos at www.youtube.com/ibmhealthcare

UCB Forward-Looking Statement This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.  UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

References

1. Epilepsy Foundation. About Epilepsy. Accessed 5/15/13.2. The Lancet. "Wanted: a global campaign against epilepsy." The Lancet no. 380 (9848):1121.

SOURCE UCB

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,217.57 +243.26 1.43%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,571.2870 +22.0610 0.48%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs